Objective 
Introduction

Certain nucleos(t)ide analogues, such as lamivudine (LAM), adefovir dipivoxil (ADV) and entecavir (ETV), have been approved recently for the treatment of chronic hepatitis B (CHB). These drugs potently suppress the replication of hepatitis B virus (HBV) genome, and improve serum alanine aminotransferase (ALT) levels and liver histological findings (1-5). However, prolonged treatment with nucleos(t)ide analogues increases the risk of emergence of drug-resistant HBV mutants. Specifically, LAM causes resistant mutation at a high rate in the YMDD (tyrosine-methionine-aspartateaspartate) motif of the HBV-DNA polymerase domain
.
LAM-resistant mutants were reported to develop in 16-32% of patients within one year of treatment, and 70% of patients within 4 years (7). Virological and biochemical breakthroughs occur in most patients with LAM-resistant mutants, and result in hepatic decompensation in a proportion of these patients.
ADV is a nucleotide analog with potent antiviral activity against both LAM-resistant and wild-type CHB (3, 4, (7) (8) (9) (10) . In many countries, ADV monotherapy is approved for CHB patients with LAM-resistant mutants, because initial reports suggested that ADV resistance would be less common and occur later in the course of treatment, compared with LAM monotherapy (11, 12 (13, 14) . On the other hand, a lower rate of emergence of ADV-resistant mutations in ADV plus LAM combination therapy was reported (13, 14 
Patients and Methods
Patients
S t u d y d e s i g n . Co n s e c u t i v e l a mi v u d i n e ( L AM) -r e s i s t a n t p a t i e n t s r e c e i v e d L AM p l u s a d e f o v i r d i p i v o x i l ( ADV) c o mb i n a t i o n t h e r a p y f o r 1 2 mo n t h s . P a t i e n t s wh o a c h i e v e d c o mp l e t e v ir o l o g i c a l r e s p o n s e ( CVR) we r e r a n d o ml y a l l o c a t e d i n t o o n e o f t wo g r o u p s . P a t i e n t s o f t h e c o mb i n at i o n g r o u p c o n t i n u e d t h e s a me c o mb i n a t i o n t h e r a p y ( c o mb i n a t i o n g r o u p ) . P a t i e n t s o f t h e o t h e r g r o u p d i s c o n t i n u e d L AM a n d s wi t c h e d t o ADV mo n o t h e r a p y wi t h i n 1 2 mo n t h s a f t e r t h e a l l o c a t i o n ( o v e r l a p / s wi t c h g r o u p ) . CVR wa s d e f i n e d a s a n u n d e t e c t a b l e s e r u m HB V-DNA l e v e l b y u s i n g t r a n s c r i p t i o n -me d i a t e d a mp l i f i c a t i o n a s s a y [ < 3 . 7 l o g g e n o me e q u i v a l e n t ( L GE ) / mL ] a t 1 2 mo n t h s a f t e r t h e c o mb i n a t i o n t h e r a p y .
Results
Patient and virological characteristics
Biochemical response to therapy
The rates of serum ALT normalization for the combination and overlap/switch groups were 73% vs. 69%, 73% vs. 
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HBV-related markers
At the time of allocation, the proportion of HBe-Agpositive patients was 33% (5/15) for the combination group and 46% (6/13) T a b l e 3 . E x p e n s e o f 2 T r e a t me n t 
